Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial

IF 25.3 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2025-07-19 DOI:10.1016/j.eururo.2025.06.003

Arvin K. George, Ranko Miocinovic, Amit R. Patel, Derek J. Lomas, Andres F. Correa, David Y.T. Chen, Ardeshir R. Rastinehad, Michael J. Schwartz, Abhinav Sidana, Kristian D. Stensland, Brian T. Helfand, Jeffrey C. Gahan, Xiaosong Meng, Alice Yu, Wayne G. Brisbane, Srinivas Vourganti, Al Baha Barqawi, Edward M. Uchio, James S. Wysock, Thomas J. Polascik, Timothy D. McClure, Jonathan Fainberg, Jonathan A. Coleman

引用次数: 0

Abstract

The PRESERVE study (NCT04972097) assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa).

查看原文本刊更多论文

不可逆电穿孔治疗中危前列腺癌患者前列腺组织消融：来自PRESERVE试验的结果

PRESERVE研究（NCT04972097）评估了纳米刀系统不可逆电穿孔（IRE）消融中危前列腺癌（PCa）患者前列腺组织的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.